aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting

On November 19, 2026 aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, reported a poster presentation featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, which is being held November 18 – 21, 2026, in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Osteosarcoma remains a significant unmet medical need with standard therapy that has not meaningfully improved survival in decades and patients facing very poor outcomes, particularly once the disease spreads to the lungs. The differentiated approach of ATYR2810 in targeting NRP2 positions it as a highly promising therapeutic candidate, as the potential to reduce metastases and sustain anti-tumor effects after treatment ends, without evidence of overt toxicity, could meaningfully improve outcomes for patients and families facing this devastating disease," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

"ATYR2810 has shown anti-tumor effects in multiple preclinical models of aggressive cancers where NRP2 is implicated, and NRP2 has been shown to play a role in osteosarcoma angiogenesis and metastasis, which is in large part driven by an immunosuppressive tumor microenvironment," said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr. "This latest research further supports that ATYR2810 can reprogram tumor-associated macrophages and that by targeting NRP2, ATYR2810 monotherapy can lead to substantial inhibition of tumor growth in osteosarcoma preclinical models, including human patient-derived orthotopic models and an aggressive syngeneic mouse model, as well as outstanding effects on tumor recurrence after removal of drug at day 25, with effects lasting out to 45 days. Furthermore, a reduction in lung metastases, a devastating complication of osteosarcoma, was also observed. We believe these findings provide a strong rationale for translating NRP2 inhibition into clinical studies."

Details of the poster presentation appear below. The poster is available on the aTyr website.

Title: Neuropilin-2 as a Therapeutic Target in Osteosarcoma: Spatial Transcriptomics and In Vivo Testing of a Clinic-Ready Anti-Neuropilin-2 Antibody
Session: Basic Science: Translational & Preclinical Research
Poster Number: 74
Date and Time: Thursday, November 19, 2026 from 5:30PM – 6:30PM KST
Location: Hall D, 3F, Coex Convention Center, Seoul, South Korea

The poster presents preclinical research evaluating the use of ATYR2810 in clinically relevant models of osteosarcoma, including primary tumors and lung metastases, utilizing spatial transcriptomics and in vivo testing. Treatment with ATYR2810 in mice was associated with reduced tumor growth and metastasis without evidence of overt toxicity. Furthermore, NRP2 was expressed on malignant osteosarcoma cells and macrophages, suggesting a potential mechanism driving disease progression.

Pediatric osteosarcoma is the most common type of primary malignant bone cancer in children and adolescents, with approximately 1,000 new cases diagnosed every year in the U.S. While osteosarcoma is a bone cancer, it can spread to other organs and tissues in the body, most commonly starting with the lungs. The current standard of care typically includes a combination of chemotherapy and surgery, including limb-sparing surgery. Limb amputation is required in approximately 10% of cases. About 40% of those treated for osteosarcoma will experience a relapse or recurrence. Research that explores the underlying causes and mechanism of metastatic disease may lead to new treatments that can address and manage recurrence, which are greatly needed.

About ATYR2810

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the neuropilin-2 (NRP2) receptor. NRP2 is a cell surface receptor that is highly expressed in many tumors and is strongly implicated in more aggressive cancer progression, drug resistance development and metastatic spread. Recent data has demonstrated that the expression of NRP2 is also associated with the development of an immunosuppressive tumor microenvironment in a variety of tumors that do not respond to classical checkpoint inhibitors. Increased NRP2 expression is associated with worse outcomes in many cancers, including osteosarcoma, triple negative breast cancer, prostate cancer and pancreatic cancer. ATYR2810 is in preclinical development for the treatment of aggressive cancers where NRP2 is implicated, having successfully completed GLP toxicology testing in non-human primates and cGMP manufacturing.

(Press release, aTyr Pharma, NOV 19, 2026, View Source [SID1234675001])

Ethics Approval for Amplia’s Accent-Mini Trial

On November 19, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) ("Amplia" or the "Company") reported that it has received ethics approval for its ACCENT-Mini trial in metastatic pancreatic cancer. Ethics approval is a key milestone in launching a clinical study, allowing patient recruitment to begin as soon as site approvals are finalised.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACCENT-Mini will evaluate daily dosed narmafotinib in combination with the chemotherapies gemcitabine and Abraxane. The trial builds on the encouraging results of the ACCENT trial, in which intermittently dosed narmafotinib plus chemotherapy improved outcomes across all measures of activity compared to chemotherapy alone. Notably, ACCENT delivered a complete response rate of 7.8% and a median overall survival of 11.1 months, with no significant changes to the tolerability profile of chemotherapy alone.

Three (3) clinical trial sites in Australia have been selected for ACCENT-Mini, and trial start-up activities at all sites are well advanced.

Safety and pharmacokinetic data from ACCENT-Mini are expected in late Q1/early Q2 2027. These data will form part of Amplia’s protocol submission to the FDA for the registrational study of narmafotinib in pancreatic cancer.

The ACCENT-Mini trial is an important step in Amplia’s strategy to build the clinical evidence for narmafotinib as a partner drug in combination treatments for hard-to-treat cancers, including pancreatic cancer. A major challenge in these cancers is that tumours often become resistant to both existing treatments and newer targeted medicines, such as KRAS inhibitors, limiting how effectively they work. Amplia believes narmafotinib has the potential to help overcome this challenge and make these treatments more effective for patients.

Amplia Therapeutics CEO and MD Dr Chris Burns commented: "We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options. Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

(Press release, Amplia Therapeutics, NOV 19, 2026, View Source [SID1234675025])

Biogen to Participate in December Healthcare Conferences

On November 19, 2026 Biogen Inc. (Nasdaq: BIIB) reported that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the Evercore 9th Annual Healthcare Conference. The webcast will be live on Monday, Nov 30, 2026, at 1:20 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anchal Joshi, Product Development and Commercialization Lead, Nephrology at Biogen, will participate in a fireside chat during the Piper Sandler 38th Annual Healthcare Conference. The webcast will be live on Thursday, Dec 3, 2026, at 9:30am ET.

To access the live webcasts, please visit the Investors section of Biogen’s website at investors.biogen.com. An archived version of the webcasts will be available for at least 30 days following the presentation.

(Press release, Biogen, NOV 19, 2026, View Source [SID1234675002])

Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

On November 19, 2026 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, reported that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and Adagene’s proprietary SAFEbody precision masking technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the first patient with ADG138 is an important step in moving our double-masked T-cell engager from preclinical research into the clinic," said Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene. "Our preclinical data showed that masking both the HER2 and CD3 binding sites preserved ADG138’s antitumor activity, including in Enhertu (DS-8201)-resistant models, while reducing cytokine release and widening the therapeutic window compared with an unmasked T-cell engager.

"Clinical experience with muzastotug, our masked anti-CTLA-4 SAFEbody in IgG1 format, now includes more than 250 patients dosed with high, repeated dosing, and continuous treatment beyond two years in some patients. Together with ADG138’s robust preclinical findings, this reinforces our confidence in extending SAFEbody technology to T-cell engagers. We look forward to evaluating ADG138’s safety and preliminary efficacy in heavily pretreated patients who have progressed after multiple lines of therapies, including standard-of-care and investigational HER2-directed antibody-drug conjugates."

The open-label Phase 1 study is designed to evaluate the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors and determine the recommended Phase 2 dose. Dose escalation will begin with a starting dose of 2 mg of ADG138, and subsequent doses will be guided by emerging clinical data.

About ADG138

ADG138 is a double-masked HER2×CD3 bispecific T cell engager designed using Adagene’s proprietary IgG-based heterodimeric format and SAFEbody precision masking technology, which covalently links masking peptides to both the HER2- and CD3-binding arms of the molecule. In its inactivated state, ADG138 is designed to minimally bind HER2-expressing cancer cells and T cells; the molecule becomes activated within the tumor microenvironment and engages T cells to selectively kill HER2-expressing tumor cells while limiting off-target toxicity.

In preclinical models, the double-masked ADG138 has achieved approximately 220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, compared to its unmasked form. Upon activation in the tumor microenvironment, ADG138 enables highly efficient T cell-mediated tumor cell killing, driving tumor regression in both HER2-high and HER2-low tumor models, including a model refractory and/or resistant to the Enhertu (DS-8201). ADG138 has also shown synergistic anti-tumor activity in combination with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. In addition, ADG138 was tolerated at doses over 300-fold higher than an unmasked T-cell engager, with markedly reduced cytokine release and a favorable pharmacokinetic profile, including a longer apparent half-life and higher systemic exposure than the parental molecule.

(Press release, Adagene, NOV 19, 2026, View Source [SID1234675026])

Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update

On November 19, 2026 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ / TASE: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported third quarter 2026 financial results and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Alpha Tau has tremendous momentum right now, and the new fantastic interim data from our REGAIN trial in recurrent glioblastoma showcase the true power of Alpha DaRT," said Alpha Tau CEO Uzi Sofer. "While the trial started with a focus on feasibility and safety, we initially begin to see responses to the treatment, and are now seeing this translate into patient survival. We will continue to follow these patients closely as their scans mature, but we believe they speak to what a potent, highly localized alpha-emitting therapy may be able to do in even the hardest-to-treat tumors. With the FDA having approved the expansion of REGAIN to up to 20 patients, which we believe may support market submission requirements for Alpha DaRT, we are pressing ahead with enrollment, while preparing for mass production and commercialization if and when we are able to secure such an authorization."

"The glioblastoma data reflect only one part of Alpha Tau’s much broader opportunity to meaningfully change how cancer is treated," continued Mr. Sofer. "In recent months we completed enrollment of 48 patients in our multicenter IMPACT pancreatic cancer pilot study, after three expansions driven by strong demand, and treated the first immunocompromised patient in our ADMIRE study. We now expect meaningful additional data from multiple trials in the coming months, including top-line data from our pivotal ReSTART trial in recurrent cSCC, initial data from IMPACT, and additional interim data from REGAIN."

"To be ready for the demand that we believe these data can generate, we continue to scale up our manufacturing capabilities. A central piece of that effort is bringing the first stage of our Hudson, New Hampshire plant online, which we are targeting to be ready for clinical trial supply by the end of 2026."

"On the corporate front, we are very pleased to have come home to Israel with our dual listing on the Tel Aviv Stock Exchange, quickly followed by our inclusion in the flagship TA-90 and TA-125 indices. With a strong balance sheet of $99.8 million, a growing body of clinical evidence across multiple tumor types, and a dense calendar of data readouts ahead of us, we believe Alpha Tau has never been better positioned to translate this momentum into meaningful impact for patients."

Recent Corporate Highlights:

● In November 2026, Alpha Tau announced new interim results from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT in recurrent glioblastoma (GBM), presented at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia by the study investigator team from The Ohio State University Comprehensive Cancer Center. As of the November 11, 2026 data cut-off, all eight patients treated in the trial were alive and median overall survival had not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who had reached response assessment. All six of these patients (100%) achieved an objective response as their best overall response under RANO criteria, comprising five complete responses (83.3%) and one partial response (16.7%) with a 58% decrease in tumor measurements. On the trial’s primary endpoints of feasibility and safety, all planned Alpha DaRT sources were successfully deployed in all eight patients (100%), with no unanticipated serious adverse events. No definitive recurrence within the treated area has been reported in any patient, although one patient developed tumor progression away from the treated area approximately nine months after treatment. The results follow the FDA’s approval in October 2026 of an Investigational Device Exemption (IDE) supplement expanding REGAIN from 10 to up to 20 patients across three U.S. academic cancer centers and adding progression-free survival as a secondary endpoint, regular quality-of-life assessments and an additional interim analysis. The Company believes that the expanded trial could generate data that may support market submission requirements for Alpha DaRT in recurrent GBM. For more information, please see here: View Source

● In October 2026, Alpha Tau announced the inclusion of its ordinary shares in the flagship TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective November 5, 2026, making Alpha Tau one of three biomed companies in the TA-125, with funds tracking these indices expected to add Alpha Tau shares to their holdings. The index inclusion follows the Company’s dual listing on the TASE in August 2026, which was undertaken in light of growing interest from Israeli investors and requests from the local investor base to trade the Company’s shares in local currency and during local business hours. The Company’s ordinary shares now trade on both Nasdaq and the TASE under the symbol DRTS.

● In August 2026, Alpha Tau announced the completion of patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic Alpha Combination Trial) pilot study of Alpha DaRT in pancreatic cancer, with 48 patients enrolled across 10 clinical centers in the United States, Canada and Israel. Originally approved for 12 patients, the study was expanded three times following strong demand, with the third expansion requested by participating clinical sites and broadening eligibility to multiple disease stages and both first-line chemotherapy regimens. IMPACT evaluates a one-time intratumoral Alpha DaRT treatment, delivered under real-time endoscopic ultrasound (EUS) guidance, as an add-on to first-line chemotherapy with either mFOLFIRINOX or gemcitabine with Abraxane (nab-paclitaxel), in patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. For more information, please see here: View Source." target="_blank" title="View Source." rel="nofollow">View Source

● In July 2026, Alpha Tau reported positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), delivered in a podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer in Boston. Among all nine evaluable patients, the combination produced a systemic objective response rate of 100%, including four complete responses and five partial responses, compared to just 19% from historical benchmarks for pembrolizumab monotherapy in this setting. Median overall survival of 18.2 months and median progression-free survival of 5.4 months compared favorably with historical benchmarks for pembrolizumab monotherapy of 12.3 months and 3.2 months, respectively. No Alpha DaRT-associated serious adverse events were observed, and the study was stopped after the recruitment of 11 patients, having surpassed its pre-specified threshold for success.

● In July 2026, Alpha Tau announced the successful treatment of the first patient in its ADMIRE (Alpha DaRT Management for Immunocompromised patients with REcurrent cSCC) study, a clinical trial evaluating intratumoral Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC), performed at Banner MD Anderson Cancer Center in Gilbert, Arizona. Immunosuppression is one of the strongest known risk factors for cSCC, and these patients are frequently excluded from clinical trials and often cannot safely receive checkpoint inhibitor immunotherapy. The prospective, multicenter, open-label, single-arm study is designed to enroll up to 28 patients at up to eight U.S. sites. For more information, please see here: View Source

Expected Upcoming Milestone Targets:

● First patient treated in U.S. locally recurrent prostate cancer pilot trial at year end 2026. For more information, please see here: View Source

● Top-line data in the ReSTART pivotal U.S. multi-center trial in recurrent cSCC in Q1 2027, followed by a potential submission to the FDA. For more information, please see here: View Source

● Additional interim data from the REGAIN recurrent GBM trial in the U.S. in Q1 2027. For more information, please see here: View Source

● Initial data from the IMPACT pancreatic cancer pilot study in H1 2027. For more information, please see here: View Source

Financial Results for the Nine Months Ended September 30, 2026

Research and Development expenses for the nine months ended September 30, 2026 were $31.7 million, compared to $22.5 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, increased clinical trial activity and payments to subcontractors, and increased raw material purchases.

Marketing expenses for the nine months ended September 30, 2026 were $0.9 million, compared to $1.4 million for the same period in 2025, primarily due to decreased employee compensation and benefits.

General and Administrative expenses for the nine months ended September 30, 2026 were $7.6 million, compared to $5.8 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, and higher professional fees.

Financial expenses, net, for the nine months ended September 30, 2026 were $58.5 million, compared to $0.6 million for the same period in 2025, primarily due to the remeasurement of warrants liability, as the public trading prices of the Company’s ordinary shares and publicly traded warrants rose over the period.

For the nine months ended September 30, 2026, the Company had a net loss of $98.9 million, or $1.09 per share, compared to a net loss of $30.5 million, or $0.39 per share, for the nine months ended September 30, 2025.

Balance Sheet Highlights

As of September 30, 2026, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $99.8 million, compared to $76.9 million at December 31, 2025.

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

(Press release, Alpha Tau Medical, NOV 19, 2026, View Source [SID1234674986])